GlassScriptPhysician profile
Alla Soyfer
NPI 1679636344
$10,503.12
in general payments reported to CMS, 2019-2025
43 companies · $2,962 in 2025
The $2,962 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $1,984 · 2023: $2,581 · 2024: $2,256 · 2025: $2,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,799.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,778.15 | 2021-2025 | |
| Novo Nordisk INC | $1,098.60 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $708.55 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $659.89 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $643.19 | 2022-2025 | |
| Glaxosmithkline, LLC. | $518.31 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Supernus Pharmaceuticals, INC. | $442.81 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $366.25 | 2022-2025 | Caplyta |
| Amgen INC. | $359.40 | 2021-2025 | Evenity, Otezla, Repatha |
| Jazz Pharmaceuticals INC. | $359.07 | 2022-2025 | |
| Axsome Therapeutics, INC. | $348.89 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.27 | 2022-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $282.20 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $235.48 | 2021-2025 | Rexulti |
| Corium, LLC | $234.06 | 2022-2025 | Azstarys |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $209.13 | 2021-2024 | Spravato |
| Pfizer INC. | $202.60 | 2021-2025 | |
| Verona Pharma, INC. | $182.86 | 2025 | Ohtuvayre |
| Alkermes, INC. | $179.72 | 2025 | Lybalvi, Aristada |
| Eisai INC. | $156.09 | 2023-2025 | |
| Abbott Laboratories | $155.20 | 2021-2025 | Freestyle Libre 3, Eterna |
| Astellas Pharma US INC | $150.08 | 2023-2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $138.66 | 2023 | Nuzyra |
| Exact Sciences Corporation | $125.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ironshore Pharmaceuticals INC. | $113.03 | 2022-2024 | Jornay Pm |
| Mannkind Corporation | $82.65 | 2023 | V-Go |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.35 | 2021-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $71.69 | 2021-2024 | Trintellix |
| Shield Therapeutics INC | $42.02 | 2024 | |
| Almatica Pharma LLC | $40.98 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $32.93 | 2021 | |
| Lundbeck LLC | $31.49 | 2023-2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $30.29 | 2023-2024 | Unithroid |
| Scilex Pharmaceuticals INC. | $21.07 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.25 | 2024 | Eliquis |
| Noven Therapeutics, LLC | $18.03 | 2023 | Xelstrym |
| Phathom Pharmaceuticals, INC. | $17.95 | 2025 | Voquezna |
| Amarin Pharma, INC. | $16.39 | 2022 | |
| Merck Sharp & Dohme LLC | $14.49 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.75 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $13.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.80 | 2023 | |
| Horizon Therapeutics Plc | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Soyfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.